Accelerate Diagnostics Q2 Revenues Down 68 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Accelerate Diagnostics today said that its revenues in the second quarter dropped three-fold year over year.

Revenues for the three months ended June 30 were $7,373, down from $22,721 a year ago, Accelerate said in its Form 10-Q filed with the US Securities and Exchange Commission. All revenues for the recently completed quarter and the year-ago period derived from royalty payments for its OptiChem products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.